Abstract
Immunoglobulins (Ig) of pooled healthy human sera were purified by affinity chromatography based on their reactivity with human IgG. This Ig fraction represent connected, natural antibodies (NAbs) and here are denoted as anti- IgG antibodies. The data revealed that IgG, IgA and IgM isotypes are constituents of anti-IgG fraction. The ability of anti- IgG antibodies to prevent infection of PBMC by HIV-1 was demonstrated. They exhibited different neutralizing activity depending on the phenotype of the tested virus. The efficacy of neutralization was comparable to monoclonal antibodies (MAbs) IgG1b12 at least for the HIV-1 92HT593B strain. These studies suggest that connected antibodies thus, constituents of immune network, could prevent infection by HIV-1. NAbs as essential components of therapeutic molecules of intravenous Ig (IVIg) have a beneficial effect on variety of immunological disorders by affecting the structure, function and dynamics of the immune network. Since, hallmark of HIV-1 infection are immunological disorders we hypothesizes that they might be corrected to some extend by anti-IgG antibodies.
Keywords: Natural autoantibodies, immune network, neutralization of HIV-1
Current HIV Research
Title: Anti-IgG Antibodies from Sera of Healthy Individuals Neutralize HIV-1 Primary Isolates.
Volume: 5 Issue: 2
Author(s): Radmila Metlas, Tanja Srdic and Veljko Veljkovic
Affiliation:
Keywords: Natural autoantibodies, immune network, neutralization of HIV-1
Abstract: Immunoglobulins (Ig) of pooled healthy human sera were purified by affinity chromatography based on their reactivity with human IgG. This Ig fraction represent connected, natural antibodies (NAbs) and here are denoted as anti- IgG antibodies. The data revealed that IgG, IgA and IgM isotypes are constituents of anti-IgG fraction. The ability of anti- IgG antibodies to prevent infection of PBMC by HIV-1 was demonstrated. They exhibited different neutralizing activity depending on the phenotype of the tested virus. The efficacy of neutralization was comparable to monoclonal antibodies (MAbs) IgG1b12 at least for the HIV-1 92HT593B strain. These studies suggest that connected antibodies thus, constituents of immune network, could prevent infection by HIV-1. NAbs as essential components of therapeutic molecules of intravenous Ig (IVIg) have a beneficial effect on variety of immunological disorders by affecting the structure, function and dynamics of the immune network. Since, hallmark of HIV-1 infection are immunological disorders we hypothesizes that they might be corrected to some extend by anti-IgG antibodies.
Export Options
About this article
Cite this article as:
Metlas Radmila, Srdic Tanja and Veljkovic Veljko, Anti-IgG Antibodies from Sera of Healthy Individuals Neutralize HIV-1 Primary Isolates., Current HIV Research 2007; 5 (2) . https://dx.doi.org/10.2174/157016207780077093
DOI https://dx.doi.org/10.2174/157016207780077093 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Study of Metabolic Parameters in Patients with Gout: A Single Center Study from Nepal
Endocrine, Metabolic & Immune Disorders - Drug Targets Bronchoalveolar Lavage in Hypersensitivity Pneumonitis: A Series of 139 Patients
Inflammation & Allergy - Drug Targets (Discontinued) To Die or Not to Die: That is the Autophagic Question
Current Molecular Medicine The DDX3 Subfamily of the DEAD Box Helicases: Divergent Roles as Unveiled by Studying Different Organisms and In Vitro Assays
Current Medicinal Chemistry Role of Toll-Like Receptors in Immune Responses to Chlamydial Infections
Current Pharmaceutical Design Enhanced Proinflammatory State and Autoimmune Activation: a Breakthrough to Understanding Chronic Diseases
Current Pharmaceutical Design Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) The Cancer Hygiene Hypothesis: From Theory to Therapeutic Helminths
Current Cancer Therapy Reviews Reverse Pharmacognosy: Application of Selnergy, a New Tool for Lead Discovery. The Example of ε-Viniferin
Current Drug Discovery Technologies The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry Peroxisome Proliferator-Activated Receptors and the Control of Inflammation
Current Drug Targets - Inflammation & Allergy Vascular Endothelium and Hypovolemic Shock
Current Vascular Pharmacology Targeting Antibody-Mediated Rejection in the Setting of ABOIncompatible Infant Heart Transplantation: Graft Accommodation vs. B Cell Tolerance
Current Drug Targets - Cardiovascular & Hematological Disorders Activation of the dsRNA-Activated Protein Kinase PKR in Mitochondrial Dysfunction and Inflammatory Stress in Metabolic Syndrome
Current Pharmaceutical Design Novel Therapeutic Strategies Targeting Vascular Redox in Human Atherosclerosis
Recent Patents on Cardiovascular Drug Discovery The Meaning of Different Forms of Structural Myocardial Injury, Immune Response and Timing of Infarct Necrosis and Cardiac Repair
Current Vascular Pharmacology Neuropeptide/Receptor Expression and Plasticity in Micturition Pathways
Current Pharmaceutical Design Leukocyte Adhesion: A Suitable Target for Anti-Inflammatory Drugs
Current Pharmaceutical Design Heme Oxygenase-1/Carbon Monoxide: Novel Therapeutic Strategies in Critical Care Medicine
Current Drug Targets Editorial (Thematic Issue: Neuroinflammation a Common Link in Neurodegenerative Neurological and Psychiatric Disorders)
Current Pharmaceutical Design